Biogen, which is also being closely watched for its Alzheimer’s phoenix from the flames drug data out this Thursday at the Clinical Trials on Alzheimer's Disease meeting, quietly announced positive phase 2 data in lupus this morning, a rare win in the field and for the biotech of late.